including novel technology such as AirSense 11 continuous positive airway pressure (CPAP) device and n30i mask. Lastly, Farrell believes the rise of GLPs will have a Botox effect on sleep apnea ...

AirSense 11. Market share gains from Philips’ product recall may be limited as affected customers can wait for a replacement unit, purchase an alternative Philips product, and ResMed’s supply ...

and reflecting the 10:1 ratio between CDIs and NYSE shares. The ex-dividend date will be November 6, 2024, for common stockholders and for CDI holders. ResMed has received a waiver from the ASX ...

Rest of the world device growth: "Sales in Europe, Asia, and other regions increased by 10%. Device sales ... of the products, AirSense 11, the communication throughout the commercial teams, and the ...

The company reported a “really solid” 10% increase ... Farrell said ResMed doesn’t spend enough time helping providers engage patients who are at or who are nearing five years using a device and ...

We forecast margin expansion as ResMed’s sales mix continues to shift to higher-margin masks and the cost inefficiency of simultaneously producing older AirSense 10 devices ceases ... positive airway ...

Air Voel Expands Product Line with the Latest ResMed CPAP Machines for Enhanced Sleep Therapy.Canada - November 8, 2024 — Air ...

Device Sales Growth: Increased by 10% globally ... showcasing strong financial performance. ResMed Inc (NYSE:RMD) is expanding the availability of its AirSense 11 platform worldwide, which ...

Financial Robustness: The financial tables from the 10-Q filing underscore ... it is crucial for ResMed to continuously monitor and optimize its supply chain and manufacturing processes to ...

But the central driver of the investment thesis is ResMed's market for sleep apnoea devices, particularly continuous positive airway pressure (CPAP ... of its new series 10 release.